Navigation Links
PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
Date:11/25/2013

London (PRWEB) November 25, 2013

PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

Scope

-Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the US from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in the US

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 15
3.3 Prognosis 16
4 Disease Management 17
4.1 Meningococcal Immunization Policy 18
4.2 US 20
4.2.1 Meningococcal Immunization Recommendations and Policies 20
4.2.2 Clinical Practice 22
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
5.3 Product Profiles – Major Brands 27
5.3.1 Menactra 27
5.3.2 Menveo 31
5.3.3 MenHibrix 34
5.3.4 Menomune 37
6 Opportunity and Unmet Need 41
6.1 Overview 41
6.2 Unmet Needs 42
6.2.1 Unmet Need: Protection Against Serogroup B Disease 42
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 43
6.2.3 Unmet Need: More Cost-Effective Vaccines 44
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 45
6.2.5 Unmet Need: Immunogenic Infant Vaccines 46
6.2.6 Unmet Need: Improved Vaccination Coverage Rates 47
6.2.7 Unmet Need: Increased Patient Awareness and Education 48
6.3 Unmet Needs Gap Analysis 49
6.4 Opportunities 49
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 49
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 50
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 51
7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Vaccines in Clinical Development 53
7.2.1 MnB rLP2086 55
7.3 Promising Vaccines in Early Clinical Development 60
8 Market Outlook 61
8.1 United States 61
8.1.1 Forecast 61
8.1.2 Key Events 65
8.1.3 Drivers and Barriers 66
9 Appendix 70
9.1 Bibliography 70
9.2 Abbreviations 80
9.3 Methodology 82
9.4 Forecasting Methodology 82
9.4.1 Vaccine Coverage 83
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion 83
9.4.3 Vaccines Included 84
9.4.4 Key Launch Dates 85
9.4.5 General Pricing Assumptions 86
9.4.6 Individual Vaccine Assumptions 86
9.4.7 Pricing of Pipeline agents 88
9.5 Physicians and Specialists Included in this Study 89
9.6 About the Authors 92
9.6.1 Authors 92
9.6.2 Reviewers 92
9.6.3 Global Head of Healthcare 93
9.7 About GlobalData 94
9.8 Disclaimer 94

List of Tables

Table 1: Symptoms of Meningococcal Disease 16
Table 2: Meningococcal Immunization Recommendation Agencies by Country 18
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 19
Table 4: Leading Vaccines for Meningococcal Disease, 2012 26
Table 5: Product Profile – Menactra 28
Table 6: Menactra SWOT Analysis, 2012 30
Table 7: Product Profile – Menveo 32
Table 8: Menveo SWOT Analysis, 2012 34
Table 9: Product Profile – MenHibrix 35
Table 10: MenHibrix SWOT Analysis, 2012 37
Table 11: Product Profile – Menomune 38
Table 12: Menomune SWOT Analysis, 2012 40
Table 13: Overall Unmet Needs – Current Level of Attainment 41
Table 14: Clinical Unmet Needs – Gap Analysis, 2012 49
Table 15: Meningococcal Vaccines – Phase Pipeline, 2012 54
Table 16: Comparison of Vaccines in Development for Meningococcal Disease, 2012 55
Table 17: Product Profile – MnB rLP2086 56
Table 18: MnB rLP2086 SWOT Analysis, 2012 59
Table 19: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012–2022 63
Table 20: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012 65
Table 21: United States Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022 66
Table 22: Key Launch Dates 85
Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 91

List of Figures

Figure 1: Membrane Structure of N. meningitidis 13
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022 54
Figure 3: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012–2022 64

Read the full report:

PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_meningococcal_vaccines_us_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/11/prweb11367899.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Dry Eye Syndrome - Current and Future Players
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022
10. PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
11. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
Breaking Medicine Technology: